3 results
The goal of this study is to prove that there is a benefit in terms of post-operative outcome not only because of the multi-modal improvements in peri-operative fluid management through the ERAS program, but also by the use of a goal-directed fluid…
Compare Progression Free Survival (PFS) for brivanib versus placebo in subjects with advanced solid tumors with FGF-2 over-expression and who have obtained stable disease after 12 weeks of treatment with brivanib separately for each tumor.
The primary objective of this study is to compare the progression free survival (PFS) following administration of IPI-504 plus best supportive care versus placebo plus best supportive care in patients with metastatic and/or unresectable…